Insulin Glulisine
- Generic Name
- Insulin Glulisine
- Brand Names
- Apidra
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 207748-29-6
- Unique Ingredient Identifier
- 7XIY785AZD
- Background
Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insul...
- Indication
用于治疗成人糖尿病。
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Hyperglycemia during critical illness
- Associated Therapies
- -
Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 281
- Registration Number
- NCT00135057
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 347
- Registration Number
- NCT00135083
Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 345
- Registration Number
- NCT00135096
- Locations
- 🇺🇸
Sanofi-aventis, Bridgewater, New Jersey, United States
Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-06-24
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 572
- Registration Number
- NCT00115570
- Locations
- 🇺🇸
Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath